Last reviewed · How we verify
GnRH agonist/antagonist
GnRH agonist/antagonist is a GnRH agonist/antagonist Small molecule drug developed by Memorial Sloan Kettering Cancer Center. It is currently FDA-approved for Prostate cancer (hormone-sensitive), Breast cancer (hormone-sensitive), Cancer treatment-related hot flashes and sexual dysfunction.
GnRH agonists/antagonists suppress gonadotropin-releasing hormone signaling to reduce sex hormone production, used in oncology to manage hormone-sensitive cancers and their treatment side effects.
GnRH agonists/antagonists suppress gonadotropin-releasing hormone signaling to reduce sex hormone production, used in oncology to manage hormone-sensitive cancers and their treatment side effects. Used for Prostate cancer (hormone-sensitive), Breast cancer (hormone-sensitive), Cancer treatment-related hot flashes and sexual dysfunction.
At a glance
| Generic name | GnRH agonist/antagonist |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Drug class | GnRH agonist/antagonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
GnRH agonists initially stimulate the pituitary gland before causing desensitization, leading to decreased luteinizing hormone and follicle-stimulating hormone, which reduces testosterone and estrogen production. GnRH antagonists directly block GnRH receptors to immediately suppress gonadotropin release. Both approaches are used in prostate cancer, breast cancer, and to mitigate hot flashes and sexual dysfunction caused by cancer therapies.
Approved indications
- Prostate cancer (hormone-sensitive)
- Breast cancer (hormone-sensitive)
- Cancer treatment-related hot flashes and sexual dysfunction
Common side effects
- Hot flashes
- Sexual dysfunction
- Injection site reactions
- Fatigue
- Bone density loss (with long-term use)
Key clinical trials
- Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments (NA)
- Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (PHASE2)
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) (PHASE3)
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (PHASE3)
- A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PHASE3)
- Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer (PHASE2)
- Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (NA)
- Radiotherapy After Prostatectomy for Node Positive Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GnRH agonist/antagonist CI brief — competitive landscape report
- GnRH agonist/antagonist updates RSS · CI watch RSS
- Memorial Sloan Kettering Cancer Center portfolio CI
Frequently asked questions about GnRH agonist/antagonist
What is GnRH agonist/antagonist?
How does GnRH agonist/antagonist work?
What is GnRH agonist/antagonist used for?
Who makes GnRH agonist/antagonist?
What drug class is GnRH agonist/antagonist in?
What development phase is GnRH agonist/antagonist in?
What are the side effects of GnRH agonist/antagonist?
What does GnRH agonist/antagonist target?
Related
- Drug class: All GnRH agonist/antagonist drugs
- Target: All drugs targeting GnRH receptor
- Manufacturer: Memorial Sloan Kettering Cancer Center — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Prostate cancer (hormone-sensitive)
- Indication: Drugs for Breast cancer (hormone-sensitive)
- Indication: Drugs for Cancer treatment-related hot flashes and sexual dysfunction
- Compare: GnRH agonist/antagonist vs similar drugs
- Pricing: GnRH agonist/antagonist cost, discount & access